Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma
NCT02278315Phase 1Completed
- Sponsor
- Cellectar Biosciences
- Start
- Feb 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Iopofosine I-131 in multiple myeloma (MM), sponsored by Cellectar Biosciences. Primary endpoint: Dose Limiting Toxicities up to 85 days. Started Feb 2015; status: completed.
02
Drugs
Iopofosine I-131
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02278315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278315.